Mechanistic modeling of hepatic transport from cells to whole body: Application to napsagatran and fexofenadine

Molecular Pharmaceutics

Volumn 6, Issue 6, 2009, Pages 1716-1733

  Poirier, Agnès ^a   Funk, Christoph ^a   Scherrmann, Jean Michel ^b   Lavé, Thierry ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Hepatocytes; Liver; Physiologically based pharmacokinetic (PBPK) modeling; Transport; Uptake

Indexed keywords

FEXOFENADINE; NAPSAGATRAN;

ACTIVE TRANSPORT; ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG PENETRATION; DRUG TRANSPORT; DRUG UPTAKE; DRUG URINE LEVEL; LIVER CELL; MALE; MICHAELIS MENTEN KINETICS; MODEL; NONHUMAN; PARAMETRIC TEST; PASSIVE TRANSPORT; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT;

ANIMALS; CELLS, CULTURED; HEPATOCYTES; KINETICS; MALE; MODELS, BIOLOGICAL; MODELS, THEORETICAL; NAPHTHALENES; PIPERIDINES; RATS; RATS, WISTAR; TERFENADINE;

EID: 71949116668     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp8002495     Document Type: Article

References (65)

1. Parrott, N.; Jones, H.; Paquereau, N.; Lave, T. Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. Basic Clin. Pharmacol. Toxicol. 2005, 96, 193-199 (Pubitemid 40387995)
2. Rostami-Hodjegan, A.; Tucker, G. T. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discovery 2007, 6, 140-148
3. Jones, H. M.; Parrott, N.; Jorga, K.; Lave, T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin. Pharmacokinet. 2006, 45, 511-542
4. Ito, K.; Houston, J. B. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm. Res. 2005, 22, 103-112
5. Soars, M. G.; Grime, K.; Sproston, J. L.; Webborn, P. J.; Riley, R. J. Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metab. Dispos. 2007, 35, 859-865
6. Ito, K.; Houston, J. B. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm. Res. 2004, 21, 785-792
7. Riley, R. J.; McGinnity, D. F.; Austin, R. P. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab. Dispos. 2005, 33, 1304-1311
8. McGinnity, D. F.; Soars, M. G.; Urbanowicz, R. A.; Riley, R. J. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab. Dispos. 2004, 32, 1247-1253
9. Wu, C. Y.; Benet, L. Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 2005, 22, 11-23.
10. Funk, C. The role of hepatic transporters in drug elimination. Expert Opin. Drug Metab. Toxicol. 2008, 4, 363-379 (Pubitemid 351728512)
11. Mizuno, N.; Niwa, T.; Yotsumoto, Y.; Sugiyama, Y. Impact of drug transporter studies on drug discovery and development. Pharmacol. Rev. 2003, 55, 425-461 (Pubitemid 37013212)
12. Shitara, Y.; Horie, T.; Sugiyama, Y. Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci. 2006, 27, 425-446 (Pubitemid 43363338)
13. Endres, C. J.; Hsiao, P.; Chung, F. S.; Unadkat, J. D. The role of transporters in drug interactions. Eur. J. Pharm. Sci. 2006, 27, 501-517
14. Dobson, P. D.; Kell, D. B. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule. Nat. Rev. Drug Discovery 2008, 7, 205-220
15. Poirier, A.; Funk, C.; Lave, T.; Noe, J. New strategies to address drug-drug interactions involving OATPs. Curr. Opin. Drug Discovery Dev. 2007, 10, 74-83.
16. Poirier, A.; Lave, T.; Portmann, R.; Brun, M. E.; Senner, F.; Kansy, M.; Grimm, H. P.; Funk, C. Design, data analysis and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model. Drug Metab. Dispos. 2008, 36, 2434-2444
17. Paine, S. W.; Parker, A. J.; Gardiner, P.; Webborn, P. J. H.; Riley, R. J. Prediction of the Pharmacokinetics of Atorvastatin, Cerivastatin and Indomethacin Using Kinetic Models Applied to Isolated Rat Hepatocytes. Drug Metab. Dispos. 2008, 36 (7), 1365-1374
18. Hatanaka, T.; Honda, S.; Sasaki, S.; Katayama, K.; Koizumi, T. Pharmacokinetic and pharmacodynamic evaluation for tissueselective inhibition of cholesterol synthesis by pravastatin. J. Pharmacokinet. Biopharm. 1998, 26, 329-347
19. Andersen, M. E.; Eklund, C. R.; Mills, J. J.; Barton, H. A.; Birnbaum, L. S. A multicompartment geometric model of the liver in relation to regional induction of cytochrome P450s. Toxicol. Appl. Pharmacol. 1997, 144, 135-144
20. Deroubaix, X.; Coche, T.; Depiereux, E.; Feytmans, E. Saturation of hepatic transport of taurocholate in rats in vivo. Am. J. Physiol. 1991, 260, G189-96.
21. Ploeger, B.; Mensinga, T.; Sips, A.; Seinen, W.; Meulenbelt, J.; DeJongh, J. The pharmacokinetics of glycyrrhizic acid evaluated by physiologically based pharmacokinetic modeling. Drug Metab. Rev. 2001, 33, 125-147 (Pubitemid 32703253)
22. Lave, T.; Portmann, R.; Schenker, G.; Gianni, A.; Guenzi, A.; Girometta, M. A.; Schmitt, M. Interspecies pharmacokinetic comparisons and allometric scaling of napsagatran, a low molecular weight thrombin inhibitor. J. Pharm. Pharmacol. 1999, 51, 85-91. (Pubitemid 29097274)
23. Matsushima, S.; Maeda, K.; Ishiguro, N.; Igarashi, T.; Sugiyama, Y. Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab. Dispos. 2008, 36 (4), 663-669
24. Matsushima, S.; Maeda, K.; Hayashi, H.; Debori, Y.; Schinkel, A. H.; Schuetz, J. D.; Kusuhara, H.; Sugiyama, Y. Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol. Pharmacol. 2008, 73 (5), 1474-1483 (Pubitemid 351574837)
25. Kamath, A. V.; Yao, M.; Zhang, Y.; Chong, S. Effect of fruit juices on the oral bioavailability of fexofenadine in rats. J. Pharm. Sci. 2005, 94, 233-239 (Pubitemid 40293320)
26. Cvetkovic, M.; Leake, B.; Fromm, M. F.; Wilkinson, G. R.; Kim, R. B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 1999, 27, 866-871
27. Luttringer, O.; Theil, F. P.; Lave, T.; Wernli-Kuratli, K.; Guentert, T. W.; de Saizieu, A. Influence of isolation procedure, extracellular matrix and dexamethasone on the regulation of membrane transporters gene expression in rat hepatocytes. Biochem. Pharmacol. 2002, 64, 1637-1650
28. Blanchard, N.; Richert, L.; Notter, B.; Delobel, F.; David, P.; Coassolo, P.; Lave, T. Impact of serum on clearance predictions obtained from suspensions and primary cultures of rat hepatocytes. Eur. J. Pharm. Sci. 2004, 23, 189-199
29. Seglen, P. O. Hepatocyte suspensions and cultures as tools in experimental carcinogenesis. J. Toxicol. Environ. Health 1979, 5, 551-560 (Pubitemid 9214773)
30. Shitara, Y.; Hirano, M.; Adachi, Y.; Itoh, T.; Sato, H.; Sugiyama, Y. In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats. Drug Metab. Dispos. 2004, 32, 1468-1475 (Pubitemid 39564568)
31. Reinoso, R. F.; Telfer, B. A.; Brennan, B. S.; Rowland, M. Uptake of teicoplanin by isolated rat hepatocytes: comparison with in vivo hepatic distribution. Drug Metab. Dispos. 2001, 29, 453-459 (Pubitemid 32275560)
32. Khor, S. P.; Bozigian, H.; Mayersohn, M. Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. II. Distribution of phencyclidine in the rat. Drug Metab. Dispos. 1991, 19, 486-490
33. Blouin, A.; Bolender, R. P.; Weibel, E. R. Distribution of organelles and membranes between hepatocytes and nonhepatocytes in the rat liver parenchyma. A stereological study. J. Cell Biol. 1977, 72, 441-455
34. Rodgers, T.; Rowland, M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J. Pharm. Sci. 2006, 95, 1238-1257 (Pubitemid 43874439)
35. Rodgers, T.; Leahy, D.; Rowland, M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J. Pharm. Sci. 2005, 94, 1259-1276 (Pubitemid 40904190)
36. Nestorov, I. Whole-body physiologically based pharmacokinetic models. Expert Opin. Drug Metab. Toxicol. 2007, 3, 235-249 (Pubitemid 47321518)
37. Rowland, M.; Balant, L.; Peck, C. Physiologically based pharmacokinetics in Drug Development and Regulatory Science: A workshop report (Georgetown University, Washington, DC, May 29-30, 2002. AAPS J. 2004, 6, 56-67.
38. Poulin, P.; Theil, F. P. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 2002, 91, 129-156 (Pubitemid 34074473)
39. Poulin, P.; Theil, F. P. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J. Pharm. Sci. 2002, 91, 1358-1370
40. Parrott, N.; Paquereau, N.; Coassolo, P.; Lave, T. An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. J. Pharm. Sci. 2005, 94, 2327-2343 (Pubitemid 41670503)
41. Lukacova, V.; Parrott, N.; Lave, T.; Fraczkiewicz, G.; Bolger, M. B.; Woltosz, W. S. General Approach to Calculation of Tissue: Plasma Partition Coefficients for Physiologically Based Pharmacokinetic (PBPK) Modeling. AAPS Annual Meeting and Exposition, Atlanta 2008, Poster, November 16-20, 2008.
42. Poulin, P.; Theil, F. P. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J. Pharm. Sci. 2000, 89, 16-35.
43. Yang, J.; Jamei, M.; Yeo, K. R.; Rostami-Hodjegan, A.; Tucker, G. T. Misuse of the well-stirred model of hepatic drug clearance. Drug Metab. Dispos. 2007, 35, 501-502
44. Carlile, D. J.; Zomorodi, K.; Houston, J. B. Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam. Drug Metab. Dispos. 1997, 25, 903-911
45. Houston, J. B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 1994, 47, 1469-1479
46. Varma, M. V.; Panchagnula, R. Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability. J. Pharm. Sci. 2005, 94, 1694-1704 (Pubitemid 41360864)
47. Mahar Doan, K. M.; Wring, S. A.; Shampine, L. J.; Jordan, K. H.; Bishop, J. P.; Kratz, J.; Yang, E.; Serabjit-Singh, C. J.; Adkison, K. K.; Polli, J. W. Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding. Pharmacology 2004, 72, 92-98 (Pubitemid 39179257)
48. Evans, A. M. Membrane transport as a determinant of the hepatic elimination of drugs and metabolites. Clin. Exp. Pharmacol. Physiol. 1996, 23, 970-974
49. Yamazaki, M.; Suzuki, H.; Sugiyama, Y. Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm. Res. 1996, 13, 497-513. (Pubitemid 26119682)
50. Kivisto, K. T.; Niemi, M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm. Res. 2007, 24, 239-247 (Pubitemid 46072183)
51. Custodio, J. M.; Wu, C. Y.; Benet, L. Z. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Delivery Rev. 2008, 60, 717-733
52. Strelevitz, T. J.; Foti, R. S.; Fisher, M. B. In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance. J. Pharm. Sci. 2006, 95, 1334-1341
53. Rippin, S. J.; Hagenbuch, B.; Meier, P. J.; Stieger, B. Cholestatic expression pattern of sinusoidal and canalicular organic anion transport systems in primary cultured rat hepatocytes. Hepatology 2001, 33, 776-782 (Pubitemid 32246624)
54. Turncliff, R. Z.; Tian, X.; Brouwer, K. L. Effect of culture conditions on the expression and function of Bsep, Mrp2, and Mdr1a/b in sandwich-cultured rat hepatocytes. Biochem. Pharmacol. 2006, 71, 1520-1529
55. Watanabe, T.; Kusuhara, H.; Maeda, K.; Shitara, Y.; Sugiyama, Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J. Pharmacol. Exp. Ther. 2009, 328, 652-662
56. Lave, T.; Parrott, N.; Grimm, H. P.; Fleury, A.; Reddy, M. Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica 2007, 37, 1295-1310 (Pubitemid 350035528)
57. Naritomi, Y.; Terashita, S.; Kagayama, A.; Sugiyama, Y. Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab. Dispos. 2003, 31, 580-588 (Pubitemid 36444167)
58. Kitamura, S.; Maeda, K.; Sugiyama, Y. Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans. Naunyn-Schmiedebergs Arch. Pharmacol. 2008, 377, 617-628
59. Kamiie, J.; Ohtsuki, S.; Iwase, R.; Ohmine, K.; Katsukura, Y.; Yanai, K.; Sekine, Y.; Uchida, Y.; Ito, S.; Terasaki, T. Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm. Res. 2008, 25, 1469-1483
60. Liu, X.; Chism, J. P.; LeCluyse, E. L.; Brouwer, K. R.; Brouwer, K. L. Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab. Dispos. 1999, 27, 637-644 (Pubitemid 29252436)
61. Ghibellini, G.; Vasist, L. S.; Leslie, E. M.; Heizer, W. D.; Kowalsky, R. J.; Calvo, B. F.; Brouwer, K. L. In vitro-in vivo correlation of hepatobiliary drug clearance in humans. Clin. Pharmacol. Ther. 2007, 81, 406-413
62. Abe, K.; Bridges, A. S.; Yue, W.; Brouwer, K. L. In vitro biliary clearance of angiotensin II receptor blockers and 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors in sandwich-cultured rat hepatocytes: comparison with in vivo biliary clearance. J. Pharmacol. Exp. Ther. 2008, 326, 983-990
63. Fukuda, H.; Ohashi, R.; Tsuda-Tsukimoto, M.; Tamai, I. Effect of plasma protein binding on in vitro-in vivo correlation of biliary excretion of drugs evaluated by sandwich-cultured rat hepatocytes. Drug Metab. Dispos. 2008, 36, 1275-1282 (Pubitemid 351929311)
64. Webborn, P. J.; Parker, A. J.; Denton, R. L.; Riley, R. J. In vitroin vivo extrapolation of hepatic clearance involving active uptake: Theoretical and experimental aspects. Xenobiotica 2007, 37, 1090-1109
65. Shitara, Y.; Sato, H.; Sugiyama, Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol. 2005, 45, 689-723. (Pubitemid 40261822)